Adma Biologics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Adma Biologics Inc in the third quarter 2026?
Adma Biologics Inc achieved a return on average equity (ROE) of 42.56 % in its third quarter 2026, this is above ADMA's average return on equity of -264.13%.
Adma Biologics Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $429 million

ROE has advanced compared to 39.59% in the second quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 7 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 263, from total ROE ranking in the second quarter 2026 at 269.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	1.7 %	2.48 %	4.53 %	36.76 %	-
Y / Y Net Income Change	36.94 %	10.53 %	68.48 %	-55.87 %	1.45 %
Net Income (TTM) in Millions	182	169	165	147	209
Return On Equity (TTM)	42.56 %	39.59 %	38.97 %	34.98 %	53.98 %
ADMA's Total Ranking	# 263	# 269	# 113	#	#
Equity (TTM) in Millions	439	408	390	477	431
Seq. Equity Change	7.42 %	4.58 %	-18.23 %	10.7 %	8.25 %
Seq. Net Income Change	31.89 %	-16.56 %	-8.2 %	35.55 %	6.46 %

Back to ADMA Management Effectiveness >> ADMA's 5 Years Annual ROE >> Compare ADMA ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 8
Sector	# 47
Overall	# 263

Return On Equity Statistics
High	Average	Low
85.68 %	-264.13 %	-6429.03 %
(Dec 31 2024)		(Sep 30 2016)

ADMA Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	477	349	135	152	141
Y / Y Equity Change	36.76 %	158.14 %	-11.03 %	7.65 %	59.97 %
Net Income in Millions	147	198	-28	-66	-72
Y / Y Net Income Change	-25.67 %	-	-	-	-
Return On Equity	30.78 %	56.64 %	-20.89 %	-43.37 %	-50.75 %

Back to ADMA Management Effectiveness >> ADMA's 5 Years Annual ROE >> Compare ADMA ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 30.78 %, due to deterioration of net income.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ADMA's' Return on Equity at Yahoo Finance
ADMA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ADMA's Competitors
Subscribers only: Roe for Adma Biologics Inc 's Suppliers
Subscribers only: Return On Equity for ADMA's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Alector Inc	112.21 %
Medpace Holdings Inc	99.76 %
3m Company	93.07 %
Exelixis Inc	85.83 %
Eli Lilly And Company	83.65 %
Rigel Pharmaceuticals Inc	73.94 %
Idexx Laboratories Inc	71.18 %
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %

Date modified: 2026-11-06T12:57:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.